BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30254104)

  • 1. A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis.
    Bødker JS; Brøndum RF; Schmitz A; Schönherz AA; Jespersen DS; Sønderkær M; Vesteghem C; Due H; Nørgaard CH; Perez-Andres M; Samur MK; Davies F; Walker B; Pawlyn C; Kaiser M; Johnson D; Bertsch U; Broyl A; van Duin M; Shah R; Johansen P; Nørgaard MA; Samworth RJ; Sonneveld P; Goldschmidt H; Morgan GJ; Orfao A; Munshi N; Johnson HE; El-Galaly T; Dybkær K; Bøgsted M
    Blood Adv; 2018 Sep; 2(18):2400-2411. PubMed ID: 30254104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis.
    Dybkær K; Bøgsted M; Falgreen S; Bødker JS; Kjeldsen MK; Schmitz A; Bilgrau AE; Xu-Monette ZY; Li L; Bergkvist KS; Laursen MB; Rodrigo-Domingo M; Marques SC; Rasmussen SB; Nyegaard M; Gaihede M; Møller MB; Samworth RJ; Shah RD; Johansen P; El-Galaly TC; Young KH; Johnsen HE
    J Clin Oncol; 2015 Apr; 33(12):1379-88. PubMed ID: 25800755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study.
    Nørgaard CH; Jakobsen LH; Gentles AJ; Dybkær K; El-Galaly TC; Bødker JS; Schmitz A; Johansen P; Herold T; Spiekermann K; Brown JR; Klitgaard JL; Johnsen HE; Bøgsted M
    PLoS One; 2018; 13(3):e0193249. PubMed ID: 29513759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation stage of myeloma plasma cells: biological and clinical significance.
    Paiva B; Puig N; Cedena MT; de Jong BG; Ruiz Y; Rapado I; Martinez-Lopez J; Cordon L; Alignani D; Delgado JA; van Zelm MC; Van Dongen JJ; Pascual M; Agirre X; Prosper F; Martín-Subero JI; Vidriales MB; Gutierrez NC; Hernandez MT; Oriol A; Echeveste MA; Gonzalez Y; Johnson SK; Epstein J; Barlogie B; Morgan GJ; Orfao A; Blade J; Mateos MV; Lahuerta JJ; San-Miguel JF
    Leukemia; 2017 Feb; 31(2):382-392. PubMed ID: 27479184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell of origin associated classification of B-cell malignancies by gene signatures of the normal B-cell hierarchy.
    Johnsen HE; Bergkvist KS; Schmitz A; Kjeldsen MK; Hansen SM; Gaihede M; Nørgaard MA; Bæch J; Grønholdt ML; Jensen FS; Johansen P; Bødker JS; Bøgsted M; Dybkær K;
    Leuk Lymphoma; 2014 Jun; 55(6):1251-60. PubMed ID: 23998255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma.
    Schinke C; Qu P; Mehdi SJ; Hoering A; Epstein J; Johnson SK; van Rhee F; Zangari M; Thanendrarajan S; Barlogie B; Davies FE; Yaccoby S; Morgan GJ
    Clin Cancer Res; 2018 Jun; 24(12):2913-2919. PubMed ID: 29563136
    [No Abstract]   [Full Text] [Related]  

  • 7. Analysis of B-cell subpopulations in monoclonal gammopathies.
    Všianská P; Říhová L; Varmužová T; Suská R; Kryukov F; Mikulášová A; Kupská R; Penka M; Pour L; Adam Z; Hájek R
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):e61-71. PubMed ID: 25578543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stable phenotype of B-cell subsets following cryopreservation and thawing of normal human lymphocytes stored in a tissue biobank.
    Rasmussen SM; Bilgrau AE; Schmitz A; Falgreen S; Bergkvist KS; Tramm AM; Baech J; Jacobsen CL; Gaihede M; Kjeldsen MK; Bødker JS; Dybkaer K; Bøgsted M; Johnsen HE
    Cytometry B Clin Cytom; 2015 Jan; 88(1):40-9. PubMed ID: 25327569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
    Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
    Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of memory B cells from thymus and its impact for DLBCL classification.
    Bergkvist KS; Nørgaard MA; Bøgsted M; Schmitz A; Nyegaard M; Gaihede M; Bæch J; Grønholdt ML; Jensen FS; Johansen P; Urup T; El-Galaly TC; Madsen J; Bødker JS; Dybkær K; Johnsen HE
    Exp Hematol; 2016 Oct; 44(10):982-990.e11. PubMed ID: 27297329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and prognostic role of annexin A2 in multiple myeloma.
    Seckinger A; Meissner T; Moreaux J; Depeweg D; Hillengass J; Hose K; Rème T; Rösen-Wolff A; Jauch A; Schnettler R; Ewerbeck V; Goldschmidt H; Klein B; Hose D
    Blood; 2012 Aug; 120(5):1087-94. PubMed ID: 22705595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in understanding prognosis in myeloma.
    Smith D; Yong K
    Br J Haematol; 2016 Nov; 175(3):367-380. PubMed ID: 27604166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse prognostic impact of bone marrow microvessel density in multiple myeloma.
    Lee N; Lee H; Moon SY; Sohn JY; Hwang SM; Yoon OJ; Youn HS; Eom HS; Kong SY
    Ann Lab Med; 2015 Nov; 35(6):563-9. PubMed ID: 26354343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma].
    Jurczyszyn A; Olszewska-Szopa M; Skotnicki AB
    Przegl Lek; 2015; 72(11):642-8. PubMed ID: 27012123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.
    Yousef S; Kovacsovics-Bankowski M; Salama ME; Bhardwaj N; Steinbach M; Langemo A; Kovacsovics T; Marvin J; Binder M; Panse J; Kröger N; Luetkens T; Atanackovic D
    Hum Vaccin Immunother; 2015; 11(7):1606-11. PubMed ID: 26001047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normal and clonal B lineage cells can be distinguished by their differential expression of B cell antigens and adhesion molecules in peripheral blood from multiple myeloma (MM) patients--diagnostic and clinical implications.
    Luque R; Brieva JA; Moreno A; Manzanal A; Escribano L; Villarrubia J; Velasco JL; López-Jiménez J; Cerveró C; Otero MJ; Martínez J; Bellas C; Roldán E
    Clin Exp Immunol; 1998 Jun; 112(3):410-8. PubMed ID: 9649209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In multiple myeloma clonotypic CD38- /CD19+ / CD27+ memory B cells recirculate through bone marrow, peripheral blood and lymph nodes.
    Rasmussen T; Lodahl M; Hancke S; Johnsen HE
    Leuk Lymphoma; 2004 Jul; 45(7):1413-7. PubMed ID: 15359642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients.
    Wu SP; Pfeiffer RM; Ahn IE; Mailankody S; Sonneveld P; van Duin M; Munshi NC; Walker BA; Morgan G; Landgren O
    Clin Cancer Res; 2016 Aug; 22(16):4039-44. PubMed ID: 26847058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in biology and therapy of multiple myeloma.
    Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
    Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma.
    Mansoor A; Akhter A; Pournazari P; Mahe E; Shariff S; Farooq F; Elyamany G; Shahbani-Rad MT; Rashid-Kolvear F
    Appl Immunohistochem Mol Morphol; 2015; 23(5):327-33. PubMed ID: 25265432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.